Drug Trial Radar · NCT00605280
A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.
Last checked: Nov 20, 2026Latest source record: Nov 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
317
Actual
Start
Sep 2005
Primary completion
Nov 2009
Study completion Jul 2011
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 31, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to test whether Macugen injected into the eye improves vision in more patients than the currently existing standard of care laser therapy. The safety of Macugen compared to standard of care laser will also be evaluated.
Conditions
- Macular Edema Associated With Diabetes Mellitus
Interventions
Standard of CareDrug
Clinicians decision to use optional laser therapy.
MacugenDrug
Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Greater Than or Equal to ≥10 Letter (or 2 Line) Improvement in Vision at 1 YearTime frame: Baseline, Year 1
Locations
73 sites in 18 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Tucson, Arizona
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Oakland, California
Pfizer Investigational Site
Santa Ana, California
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Hamden, Connecticut
Pfizer Investigational Site
Fort Lauderdale, Florida
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
Augusta, Georgia
Pfizer Investigational Site
‘Aiea, Hawaii
Pfizer Investigational Site
Indianapolis, Indiana
Pfizer Investigational Site
Wichita, Kansas
Pfizer Investigational Site
Boston, Massachusetts
Pfizer Investigational Site
Detroit, Michigan
Pfizer Investigational Site
Lynbrook, New York
Pfizer Investigational Site
New York, New York
Pfizer Investigational Site
Charlotte, North Carolina
Pfizer Investigational Site
Pittsburgh, Pennsylvania
Pfizer Investigational Site
West Columbia, South Carolina
Pfizer Investigational Site
Abilene, Texas
Pfizer Investigational Site
Fort Worth, Texas
Pfizer Investigational Site
Houston, Texas
Pfizer Investigational Site
McAllen, Texas
Pfizer Investigational Site
San Antonio, Texas
Pfizer Investigational Site
Temple, Texas
Pfizer Investigational Site
Milwaukee, Wisconsin
Pfizer Investigational Site
East Melbourne, Australia
Pfizer Investigational Site
Westmead, New South Wales, Australia
Pfizer Investigational Site
Innsbruck, Austria
Pfizer Investigational Site
Vienna, Austria
Pfizer Investigational Site
Porto Alegre, Brazil
Pfizer Investigational Site
São Paulo, Brazil
Pfizer Investigational Site
São Paulo, Brazil
Pfizer Investigational Site
Gioania, Goiás, Brazil
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Bogotá, Colombia
Pfizer Investigational Site
Brno, Czechia
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.